A detailed history of Affinity Asset Advisors, LLC transactions in Xenon Pharmaceuticals Inc. stock. As of the latest transaction made, Affinity Asset Advisors, LLC holds 1,161,237 shares of XENE stock, worth $46.1 Million. This represents 8.14% of its overall portfolio holdings.

Number of Shares
1,161,237
Previous 1,144,021 1.5%
Holding current value
$46.1 Million
Previous $45 Million 1.12%
% of portfolio
8.14%
Previous 7.78%

Shares

13 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q4 2024

Feb 13, 2025

BUY
$38.14 - $45.74 $656,618 - $787,459
17,216 Added 1.5%
1,161,237 $45.5 Million
Q3 2024

Nov 13, 2024

BUY
$36.12 - $43.96 $5.41 Million - $6.58 Million
149,794 Added 15.07%
1,144,021 $45 Million
Q2 2024

Aug 14, 2024

BUY
$36.25 - $43.75 $5.69 Million - $6.86 Million
156,840 Added 18.73%
994,227 $38.8 Million
Q1 2024

May 14, 2024

BUY
$42.66 - $50.04 $16.1 Million - $18.9 Million
377,387 Added 82.04%
837,387 $36 Million
Q4 2023

Feb 13, 2024

BUY
$28.7 - $46.46 $4.58 Million - $7.41 Million
159,562 Added 53.11%
460,000 $21.2 Million
Q3 2023

Nov 14, 2023

BUY
$34.16 - $39.73 $8.2 Million - $9.54 Million
240,062 Added 397.61%
300,438 $10.3 Million
Q2 2023

Aug 14, 2023

SELL
$34.84 - $43.54 $1.03 Million - $1.29 Million
-29,624 Reduced 32.92%
60,376 $2.32 Million
Q1 2023

May 15, 2023

BUY
$33.46 - $40.35 $1.34 Million - $1.61 Million
40,000 Added 80.0%
90,000 $3.22 Million
Q4 2022

Feb 13, 2023

BUY
$33.06 - $39.43 $1.65 Million - $1.97 Million
50,000 New
50,000 $1.97 Million
Q2 2022

Aug 12, 2022

SELL
$25.44 - $35.16 $2.04 Million - $2.81 Million
-80,000 Closed
0 $0
Q1 2022

May 13, 2022

SELL
$25.09 - $33.13 $1.77 Million - $2.34 Million
-70,500 Reduced 46.84%
80,000 $2.45 Million
Q4 2021

Feb 11, 2022

BUY
$15.6 - $35.4 $1.57 Million - $3.56 Million
100,500 Added 201.0%
150,500 $4.7 Million
Q3 2021

Nov 12, 2021

BUY
$14.86 - $19.45 $743,000 - $972,500
50,000 New
50,000 $764,000

Others Institutions Holding XENE

About Xenon Pharmaceuticals Inc.


  • Ticker XENE
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 62,263,500
  • Market Cap $2.47B
  • Description
  • Xenon Pharmaceuticals Inc., a clinical-stage biopharmaceutical company, engages in developing therapeutics to treat patients with neurological disorders in Canada. Its clinical development pipeline includes XEN496, A Kv7 potassium channel opener that is Phase III clinical trials for the treatment of KCNQ2 developmental and epilepsy encephalopath...
More about XENE
Track This Portfolio

Track Affinity Asset Advisors, LLC Portfolio

Follow Affinity Asset Advisors, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Affinity Asset Advisors, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Affinity Asset Advisors, LLC with notifications on news.